Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 18NET 13Gastrointestinal 13Thoracic 3Sarcoma 3Head & Neck 3Dermatologic 3CNS 3Other solid neoplasm 2Gynecologic 1Breast 1

Conditions

Ovarian Neoplasms 799Uterine Cervical Neoplasms 537Endometrial Neoplasms 459Breast Neoplasms 221Fallopian Tube Neoplasms 198Colorectal Neoplasms 179Carcinoma, Non-Small-Cell Lung 163Neoplasms 137Stomach Neoplasms 127Pancreatic Neoplasms 118Prostatic Neoplasms 107Neoplasm Metastasis 107Melanoma 107Lung Neoplasms 103Carcinoma, Ovarian Epithelial 92Triple Negative Breast Neoplasms 91Squamous Cell Carcinoma of Head and Neck 82Esophageal Neoplasms 77Head and Neck Neoplasms 75Carcinoma, Renal Cell 75Urinary Bladder Neoplasms 74Uterine Neoplasms 66Vulvar Neoplasms 64Colonic Neoplasms 59Peritoneal Neoplasms 58Carcinoma, Hepatocellular 58Uterine Cervical Dysplasia 57Sarcoma 52Carcinoma, Transitional Cell 48Papillomavirus Infections 47

Interventions

sapanisertib 1aflibercept 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenoma, Islet Cell × Gynecologic × 1 year × Clear all
NCT02159989 2025-10-20

Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 1 Completed
83 enrolled 21 charts
GastrointestinalGynecologic

Fibrolamellar hepatocellular carcinoma, Adenoma, Islet Cell, Neoplasm Metastasis, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡